Edison Investment Research - Egalet (EGLTQ) QuickView: Innovating abuse deterrent drugs

Report

Edison Investment Research

QuickView: Innovating abuse deterrent drugs

In late December, Egalet submitted an NDA for its Arymo ER abuse-deterrent (AD) morphine tablet â€“ a widely prescribed opiate with few AD competitors. Management expects to complete clinical trials in early 2017 to support a mid 2017 NDA filing for its AD oxycodone tablet. If approved, this will open Egalet to the $2.5bn market for oxycontin with a proprietary AD formulation.

01/04/2016 2 EN

Underlying

Egalet

Egalet is a pharmaceutical company developing, manufacturing and commercializing treatment for pain and other conditions. The company has two pain products, SPRIX

See profile

US28226B1044 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

BusinessWire

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover Losses Suffered by Investors in Egalet Corporation

NEW YORK--(BUSINESS WIRE)-- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired shares of Egalet Corporation (“Egalet”) (NASDAQ: EGLT) between December 15, 2015 and January 9, 2017. You are hereby notified that Levi & Korsinsky has commenced the class action Mineff v. Egalet Corporation, et al. (Case No. 2:17-cv-00390-MMB) in the USDC for the Eastern District of Pennsylvania. Click here to view the complaint. To get more information go to: ...

March 13, 2017 March 13, 2017 1 EN

BusinessWire

EGLT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Egalet Corporation and a Lead Plaintiff Deadline of March 28, 2017

NEW YORK--(BUSINESS WIRE)-- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Eastern District of Pennsylvania on behalf of investors who purchased Egalet Corporation (NASDAQ:EGLT) securities between December 15, 2015 and January 9, 2017. Click here to learn about the case: http://www.wongesq.com/pslra/egalet-corporation. There is no cost or obligation to you. The complaint alleges that, among other allegations, throughout the Class Period, Egalet made materia...

March 8, 2017 March 8, 2017 1 EN

BusinessWire

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Egalet Corporation To Contact The Firm

STEVENSON, Md.--(BUSINESS WIRE)-- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Eastern District of Pennsylvania on behalf of purchasers of Egalet Corporation (Nasdaq: EGLT) (“Egalet” or the “Company”) securities during the period between December 15, 2015 and January 9, 2017, inclusive (the “Class Period”). Investors who wish to become proactively involved in the litigation have until March 28, 2017 t...

March 3, 2017 March 3, 2017 1 EN

IP Group - Several potential portfolio catalysts on the horizon

IP Group’s NAV declined by 13% in total return (TR) terms in FY23, affected by continued soft valuations across venture capital (VC) markets, as well as funding delays at some of its holdings. That said, management indicated that many of IP Group’s portfolio companies continued to make strong progress. Its maturing portfolio offers a number of potential NAV triggers and is now available at a wide 59% discount to NAV. We note that, as at end-2023, only 14% of IP Group’s portfolio was valued based on funding rounds completed more than 12 months ago and 46% of its private portfolio was valued by ...

9h / 5m 9h / 5m 1 EN

Sean Conroy

Sean Conroy

Actinogen Medical - First patient dosed in Phase IIb XanaMIA study

Actinogen Medical announced that the first randomised patient in its Phase IIb XanaMIA trial of lead candidate Xanamem received their first treatment on Friday 12 April. This study is designed to enrol c 220 patients with cognitive impairment (CI) associated with biomarker-positive mild-to-moderate Alzheimer’s disease (AD), as confirmed through an elevated level of phosphorylated Tau-181 (pTau-181) protein in their blood at baseline. The study has commenced at 13 Australian sites and will concentrate on domestic sites for the first c 100 patients, and initial efficacy and safety results will b...

11h / 23m 11h / 23m 1 EN

Sean Conroy

Sean Conroy

Cereno Scientific - CS014 (thrombosis) progresses towards the clinic

Cereno Scientific has taken a step closer to advancing its second asset, CS014, a novel HDAC inhibitor with epigenetic effects, to the clinic with the submission of the clinical trial application (CTA) to the European Medicines Agency (EMA). The CTA is for the first-in-human Phase I trial for CS014, which Cereno is developing for thrombosis prevention, without increased risk of bleeding. We believe this has the potential to address the main limitation of current standard-of-care antithrombotic medicines and offers a sizeable opportunity for Cereno (backed by supportive preclinical data). Subje...

11h / 45m 11h / 45m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Innovating abuse deterrent drugs

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed a Complaint to Recover Losses Suffered by Investors in Egalet Corporation

EGLT SHAREHOLDER ALERT: The Law Offices of Vincent Wong Reminds Investors of a Class Action Involving Egalet Corporation and a Lead Plaintiff Deadline of March 28, 2017

DEADLINE ALERT: Brower Piven Alerts Shareholders Of Approaching Deadline In Class Action Lawsuit And Encourages Those With Losses In Excess Of $100,000 From Investment In Egalet Corporation To Contact The Firm

IP Group - Several potential portfolio catalysts on the horizon

Actinogen Medical - First patient dosed in Phase IIb XanaMIA study

Cereno Scientific - CS014 (thrombosis) progresses towards the clinic

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe